E.8 Tricuspid regurgitation

Figure 37: RVEF per 5% higher (continuous variable) on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)




Figure 38: RVEF <46% vs ≥46% on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)

-			RVEF <46% on CMR	RVEF ≥ 46% on CMR	CMR Hazard Ratio		Hazard Ratio				
Study or Subgroup	log[Hazard Ratio]	SE	Total	Total	IV, Fixed, 95% CI		IV, Fixed, 95% Cl				
35.1.1 Cardiac death	following TR surger	y - unadj	justed estimate from	n data provided							
Park 2016	1.6214	0.6018	23	52	5.06 [1.56, 16.46]						
						0.05	0.2	i (5	20'	
							Favours RVEF <46% on CMR	Favours RVEF ≥46	% on CMR		

Figure 39: RV-ESVI 10 ml/m² increase (continuous variable) on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)




Figure 40: RV-ESVI ≥76 ml/m² vs. <76 ml/m² on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)





Figure 41: RVEF per 5% higher (continuous variable) on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)



242 Heart valve disease: evidence reviews for cardiac MRI and cardiac CT Final [November 2021]

Figure 42: RVEF <46% vs ≥46% on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)




Figure 43: RV-ESVI 10 ml/m² increase (continuous variable) on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)




Figure 44: RV-ESVI ≥76 ml/m² vs. <76 ml/m² on cardiac MRI in severe isolated functional TR undergoing TR surgery (54.7% in NYHA class III/IV)

